InflaRx N.V. (IF0)
XFRA 
Summary
IF0 Chart
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Get InflaRx alerts:Sign UpIzicopan positioned as a next-generation C5aR inhibitor Riedemann described izicopan as an oral agent designed to block the C5a receptor, a pathway he called a “critical driver of inflammatory cascade.
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18.
InflaRx N.V. (IF0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has InflaRx N.V. ever had a stock split?
InflaRx N.V. Profile
| Biotechnology Industry | Healthcare Sector | Niels C. Riedemann CEO | XFRA Exchange | NL0012661870 ISIN |
| DE Country | 65 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
InflaRx N.V. is a clinical-stage biopharmaceutical company based in Jena, Germany, with operations extending to the United States, focused on the discovery and development of inhibitors leveraging its proprietary C5a technology. Founded in 2007, originally as Fireman B.V., the company underwent a rebranding to InflaRx N.V. in 2017. It specializes in targeting C5a, a key inflammatory mediator implicated in a range of autoimmune and inflammatory diseases. InflaRx's innovative approach aims to mitigate the progression of these diseases by inhibiting the action of C5a. The company engages in significant collaborations, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc., underscoring its commitment to advancing its pipeline of treatments through strategic partnerships.
Products and Services
- Vilobelimab:
An intravenously administered first-in-class anti-C5a monoclonal antibody. Vilobelimab has completed a Phase III clinical trial for the treatment of hidradenitis suppurativa, a chronic inflammatory skin disease. It is also undergoing Phase II trials for anti-neutrophil cytoplasm antibody-associated vasculitis, a severe autoimmune disease; a Phase IIa exploratory study for pyoderma gangraenosum, another chronic inflammatory skin disorder; and a Phase II trial for PD-1/PD-L1 inhibitor-resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.
- INF904:
An oral, small molecule drug candidate designed for the management of chronic inflammatory and autoimmune diseases. Currently under development, INF904 represents InflaRx's efforts to expand its portfolio into oral therapeutics for wider applications in autoimmunity and inflammation.
- IFX002:
This candidate is in the pre-clinical development stage and seeks to offer a new treatment option for chronic inflammation and autoimmune diseases. IFX002 illustrates InflaRx's commitment to diversifying its strategies against inflammatory mediators beyond its flagship C5a technology.
- Gohibic (vilobelimab) for COVID-19 and broader ARDS:
A specialized application of vilobelimab, targeting the treatment of COVID-19 and broader Acute Respiratory Distress Syndrome (ARDS). In this context, InflaRx aims to address the inflammatory component of these respiratory conditions, reflecting the company's adaptability in applying its technologies to emergent global health challenges.
